HRTXHERON THERAPEUTICS, INC. /DE/
Pharmaceutical Preparations
- Revenue
- $155M
- 7.4% YoY
- Operating margin
- -1.6%
- 79% YoY
- EBITDA
- −$224K
- 98% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $86M | $108M | $127M | $144M | $155M | 7.4% |
| Operating income | −$218M | −$175M | −$111M | −$12M | −$3M | 78% |
| Net income | −$221M | −$182M | −$111M | −$14M | −$20M | 43% |
| Operating cash flow | −$203M | −$147M | −$59M | −$23M | −$28M | 22% |
| Capex | $3M | $2M | $2M | $2M | $317K | 81% |
| Stock-based comp | $47M | $43M | $33M | $13M | $10M | 20% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 6 | 120 |
| FY2024 | — | — | 7 | 91 |
| FY2023 | — | — | 8 | 92 |
| FY2022 | — | — | 12 | 89 |
| FY2021 | — | — | 43 | 99 |